FACS: Tested by flow cytometric analysis of human peripheral blood leukocytes and cell agglutination assay. Can be used at approximately 0.1 mg per million cells. IHC-Fr: Use at an assay dependent dilution. Agglutination studies: The antibody agglutinates untreated RBCs but it fails to agglutinate papain-treated cells. Optimal dilutions/concentrations should be determined by the end user.
The antibody recognizes N-terminal, homologous portion of glycophorins A (GPA) and B (GPB), (strongly to GPA, and weakly to GPB). The antibody is useful in erythroid cell development studies, because HIR2 antigen is expressed on early erythroblasts, late erythroblasts, erythroblasts, mature erythrocytes and the cells of erythroid cell lines K562 and HEL, but not on all other cells (mature erythrocytes are characteristically CD235a positive and CD45 and CD71 negative).
Phosphate buffered saline pH 7.4 containing 15mM sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide (Human) (N terminal).
Protein G purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Glycophorin A (Mns Blood Group),Cd235A,Gpa,Gperik,Gpsat,Hgpmiv,Hgpmixi,Hgpsta(C),Mn,Mns,Pas-2,Gypa
Glycophorins A (GPA) and B (GPB) which are single pass membrane sialoglycoproteins. GPA is the carrier of blood group M and N specificities, while GPB accounts for S and U specificities. GPA and GPB provide the cells with a large mucin like surface and it has been suggested this provides a barrier to cell fusion, so minimizing aggregation between red blood cells in the circulation.